Search results for: hip OA

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Michele B. Kaufman, PharmD, BCGP | May 15, 2018

After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…

2014 ACR/ARHP Annual Meeting: Alive and Growing

Susan Bernstein | February 1, 2015

Bone disorders play role in development of osteoarthritis pain, progression

New Insights into CPPD

Robert Terkeltaub, MD | October 1, 2013

Progress in research, outcomes, diagnosis, and treatment of calcium pyrophosphate dihydrate crystal deposition disease

A&R and AC&R Abstracts: Bisphosphonates

Staff | February 3, 2012

Want to learn more about bisphosphonates and fractures? Check out these abstracts from Arthritis & Rheumatism and Arthritis Care & Research.

Drug Updates

Michele B. Kaufman, PharmD, BCGP | July 12, 2011

Information on New Approvals and Medication Safety

Are NSAIDS Even Less Safe Than We Thought?

Mary Desmond Pinkowish | March 18, 2011

Recent meta-analysis points to MI risks, but many questions remain

Get the Most Out of Joint Replacement

Marie D. Westby, BSc(PT) | September 1, 2008

Exercise can improve the outcomes in hip and knee replacement surgery

Answering the Call: Anisha Dua, MD, MPH, Looks Ahead to New Role as Committee on Training Chair

Carina Stanton | January 16, 2025

Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.

Precision Medicine on a Population Level: Can Digital Health Technology Improve Access to Rheumatologic Care?

Daniel H. Solomon, MD, MPH, & Andrew Concoff, MD, FACR | January 16, 2025

Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…

Hit the Ground Running with New Insurance Subcommittee Chair Michael Feely, MD

Carina Stanton | January 11, 2025

Dr. Feely discusses his previous work with the College, his current work as a practicing rheumatologist and how he will lead continued advances on the insurance front.